Chemical structure of PTC596 PTC Therapeutics oral, brain-penetrant tubulin-binding agent

CNS-penetrant tubulin-binder (colchicine site)

oral agent in Ph. I for leiomyosarcoma

not a P-gp substrate, formerly BMI-1 inh.

Molecular Cancer Therapeutics

PTC Therapeutics, South Plainfield, US

The PTC Therapeutics oral, brain-penetrant tubulin-binding agent, PTC596, is in Ph. I clinical studies for advanced solid tumors (starting dose of 200 mg PO BIW). We recently highlighted encequidar, a P-gp…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.